Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fadraciclib (CYC065) in advanced cancers
NCT02552953Phase 1Completed
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Start
- Sep 2015
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fadraciclib in solid tumor and lymphoma (3 arms), sponsored by Cyclacel Pharmaceuticals, Inc. Primary endpoint: Number of patients who experience dose-limiting toxicities. Started Sep 2015; status: completed.
02
Drugs
fadraciclib
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT02552953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02552953.